{"entity":{"id":"nct06427941","kind":"trial","name":"A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Sol","aka":[],"tldr":"A phase 1/2 trial of Tislelizumab, Bevacizumab in hepatocellular carcinoma and non-small-cell lung cancer, run by BeOne Medicines, now recruiting.","summary":"A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT06427941 by BeOne Medicines, with 630 participants planned, started 2024-07-23 and due to reach its primary completion in 2027-03-31. Interventions recorded: BGB-B2033, Tislelizumab, Bevacizumab. Conditions listed: Metastatic Hepatocellular Carcinoma, Local Advanced Hepatocellular Carcinoma, Alpha-fetoprotein (AFP)-Producing Gastric Cancer, Extragonadal Yolk Sac Tumors. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06427941","url":"https://clinicaltrials.gov/study/NCT06427941"}],"tags":["ctgov-ingest"],"related":[],"cancers":["hcc","nsclc","sclc"],"sections":[],"technologies":["antiangiogenic","checkpoint-inhibitor","monoclonal-antibody"],"targets":[],"drugs":["tislelizumab","bevacizumab"],"companies":["beone"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06427941","phase":"1/2","setting":"A Phase 1/2 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Selected Advanced or Metastatic Solid Tumors","sponsor":"BeOne Medicines","participation":[{"nct":"NCT06427941","source":"https://clinicaltrials.gov/study/NCT06427941","fetchedAt":"2026-10-07T16:54:39.727Z","studySha256":"d0f32fb4c3f686697e769e14615454df3bfdb25fdf3a10b297b86cbd597c17a5","overallStatus":"RECRUITING","lastUpdatePosted":"2026-09-16","leadSponsor":"BeOne Medicines","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":630,"enrolmentType":"ESTIMATED","siteCount":51,"recruitingSiteCount":50,"countries":["Brazil","China","France","Italy","Japan","New Zealand","Puerto Rico","South Korea","United States"]}],"started":"2024-07-23","startedType":"actual","enrolled":630,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06427941/","neighbours":{"cancer":[{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"technology":[{"id":"antiangiogenic","kind":"technology","name":"Anti-angiogenic therapy","route":"/technologies/antiangiogenic/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"}],"drug":[{"id":"bevacizumab","kind":"drug","name":"Bevacizumab","route":"/drugs/bevacizumab/"},{"id":"tislelizumab","kind":"drug","name":"Tislelizumab","route":"/drugs/tislelizumab/"}],"company":[{"id":"beone","kind":"company","name":"BeOne Medicines (formerly BeiGene)","route":"/companies/beone/"}]}}